U.S. Blood Ketone Meter Market (2025 - 2033)

U.S. Blood Ketone Meter Market Summary

The U.S. blood ketone meter market size was estimated at USD 106.1 million in 2024 and is projected to reach USD 115.1 million by 2033, growing at a CAGR of 0.9% from 2025 to 2033. Some of the factors contributing to market growth include the increasing prevalence of diabetes, growing health awareness among consumers and rising adoption of ketogenic and low-carbohydrate diets.

The growth is driven by increasing interest in metabolic health management, particularly within the keto diet community and among people who need to monitor Blood ketone meters are used to monitor ketone levels for managing Type 1 Diabetes (T1D), tracking nutritional ketosis in ketogenic diets, and supporting the treatment of neurological conditions such as epilepsy. A 2023 study titled “Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes” investigated whether routine point-of-care capillary blood ketone measurements in fasted, symptom-free individuals with T1D could predict future DKA events.

The findings showed that routine capillary ketone monitoring can help identify individuals at elevated risk of future DKA, highlighting the potential value of emerging technologies such as Continuous Ketone Monitoring (CKM) for early intervention and prevention. With the growing awareness of DKAprevention, such evidence will likely broaden the adoption and expansion of the U.S. blood ketone meter market.

The U.S. blood ketone meter industry is shaped by evolving care delivery models and payer policy reforms. The rise of telehealth, boosted significantly by the COVID-19 pandemic, has made diabetes management more accessible by enabling remote consultations, real-time data sharing, and timely treatment adjustments. This shift supports more consistent use of monitoring tools such as blood ketone meters, especially for patients managing T1D or adhering to ketogenic therapies. In 2024, approximately 20,000 children and adolescents under the age of 20 in the U.S. were newly diagnosed with T1D. This increase is driven by inherited risk, environmental factors, and changes in early-life habits (such as diet and infections).

The MDPI 2025 study titled “Severe Diabetic Ketoacidosis in Children with Type 1 Diabetes” highlighted key findings on ketone monitoring. The study found that blood ketone testing was more effective than urine ketone testing in early DKA detection and management.

Type Insights

The blood glucose and ketone monitoring segment dominated the U.S. blood ketone meter industry and accounted for a revenue share of 51.6% in 2024, owing to the rising prevalence of T1D, increased awareness of DKA prevention, and growing adoption of ketogenic diets for metabolic health and weight management. Advances in dual-function devices that measure glucose and ketones from a single meter have enhanced convenience and patient compliance. In addition, the expansion of telehealth, improvements in insurance coverage for remote monitoring tools, and the integration of digital health platforms are making ketone tracking more accessible and clinically actionable. These advancements collectively support better chronic disease management and fuel broader acceptance of health-monitoring wearables across the healthcare system. In June 2024, the U.S. Department of Health and Human Services (HHS) announced plans to launch a major campaign encouraging the use of wearable health devices to monitor metrics such as glucose and heart rate. The initiative aims to promote self-health management and reduce reliance on costly medications, envisioning nationwide adoption within 4 years.

The blood ketone monitoring segment is expected to grow at the fastest CAGR of 1.3% over the forecast period. Traditionally, ketone levels have been measured through occasional finger-stick tests, but this method often misses the early stages of ketone buildup, which can lead to diabetic ketoacidosis. There has been research, clinical interest, and industry investment in CKM devices, with prototypes already under development and expected to become commercially available shortly.

Application Insights

The human segment accounted for the highest revenue share in 2024. The growing popularity of ketogenic diets for weight loss, epilepsy management, and metabolic health has led health-conscious individuals to adopt personal ketone monitoring tools. Rising awareness of early DKA symptoms, advancements in user-friendly at-home testing devices, and expanding telehealth services have made it easier for individuals to self-monitor and share ketone data with healthcare providers.

The veterinary segment is expected to grow over the forecast period. This is owing to the rising incidence of metabolic disorders such as bovine ketosis in dairy cattle and DKA in companion animals such as dogs and cats. Increased awareness among veterinarians and livestock owners about the economic and health impacts of delayed diagnoses has led to a greater adoption of point-of-care ketone testing. Advancements in portable and easy-to-use veterinary-specific ketone meters have made monitoring more accessible for veterinarians and pet owners.

End Use Insights

The hospitals segment accounted for the largest revenue share in 2024. Hospitals rely on rapid point-of-care ketone testing for timely diagnosis and treatment, especially in emergency, ICU, and pediatric settings. The growing demand for portable devices that offer immediate results and integrate with electronic medical records supports clinical efficiency and coordinated care.

The home care settings segment is expected to experience the fastest CAGR over the forecast period. With more individuals managing type 1 diabetes, following ketogenic diets, or using insulin therapies, the need for convenient, accurate at-home ketone testing is increasing. Recent advancements in portable meter accuracy and expanded online access through e-commerce platforms have boosted consumer confidence and convenience, reinforcing the market shift toward home-based metabolic care.

Key U.S. Blood Ketone Meter Company Insights

Some key players in the U.S. blood ketone meter industry are TaiDoc Technology Corporation, EKF Diagnostics Holdings plc, and Abbott.

• TaiDoc specializes in medical diagnostic and monitoring devices, with a strong presence in the U.S. home and clinical care markets. Its portfolio includes multi-function meters that measure blood glucose and ketones, catering to individuals managing diabetes and those following ketogenic therapies.

Recent Developments

• In 2024, Nova Biomedical launched its next-generation StatStrip Glucose/Ketone Hospital Meter in the U.S. It is the only FDA-cleared glucose meter for all critically ill patient samples and helps measure blood ketones.

U.S. Blood Ketone Meter Market